|
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.
|
 |
|
Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
|
|
|
GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.
|
|
|
The company plans to focus its resources on conducting clinical trials for CD388 influenza prevention therapy.
|
|
|
Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination campaign.
|
|
|
The authorisation enables a twice-yearly, ten-minute subcutaneous injection to treat RMS and PPMS.
|
|
|
The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.
|
|
